A. Jay Holmgren is with the Harvard Business School, Harvard University, Boston, MA. Alyssa Botelho is with the Medical Scientist Training Program, Harvard Medical School, Boston, MA, and the Department of the History of Science, Harvard University, Cambridge, MA. Allan M. Brandt is with the Department of Global Health and Social Medicine, Harvard Medical School, Boston, and the Department of the History of Science, Harvard University, Cambridge.
Am J Public Health. 2020 Aug;110(8):1191-1197. doi: 10.2105/AJPH.2020.305696. Epub 2020 Jun 18.
Prescription drug monitoring programs (PDMPs) have become a widely embraced policy to address the US opioid crisis. Despite mixed scientific evidence on their effectiveness at improving health and reducing overdose deaths, 49 states and Washington, DC have adopted PDMPs, and they have received strong bipartisan legislative support. This article explores the history of PDMPs, tracking their evolution from paper-based administrative databases in the early 1900s to modern-day electronic systems that intervene at the point of care. We focus on two questions: how did PDMPs become so widely adopted in the United States, and how did they gain popularity as an intervention in the contemporary opioid crisis? Through this historical approach, we evaluate what PDMPs reflect about national drug policy and broader cultural understandings of substance use disorder in the United States today. ( 2020;110:1191-1197. 10.2105/AJPH.2020.305696).
处方药物监测计划(PDMPs)已成为解决美国阿片类药物危机的一项广泛接受的政策。尽管在改善健康和减少过量死亡方面的有效性存在混合的科学证据,但 49 个州和华盛顿特区已经采用了 PDMPs,并且它们得到了两党立法的大力支持。本文探讨了 PDMPs 的历史,追踪其从 20 世纪初的基于纸质的行政数据库发展到现代在护理点进行干预的电子系统的演变过程。我们关注两个问题:PDMPs 是如何在美国得到如此广泛采用的,以及它们是如何作为当代阿片类药物危机干预措施而流行起来的?通过这种历史方法,我们评估了 PDMPs 反映了当今美国国家药物政策和更广泛的物质使用障碍文化观念的哪些方面。(2020;110:1191-1197. 10.2105/AJPH.2020.305696)。